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Abstract Esophageal squamous cell carcinoma have been
frustrating to treat, with slow progress made on extending
survival. Immunotherapy targeting immune checkpoints, T
cells, and infiltrating lymphocytes has shown promise in early
studies. The efficacy of pembrolizumab and nivolumab is en-
couraging. Anti-chemokine receptors and oncolytic viruses
are also making headway against these stubborn tumors; im-
proved results when immune checkpoint inhibitors are com-
bined with radiation therapy are eagerly anticipated. Adoptive
T cell therapy and vaccines are also under development. The
importance of a multidisciplinary approach cannot be empha-
sized enough.
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Introduction
The two histological subtypes of esophageal/esophagogastric
junction (EGJ) carcinoma, adenocarcinoma (ADC) and squa-
mous cell carcinoma (SCC), have different risk factors and
clinicopathological features. Although not all clinical trials
have broken down their results according to subtype, the dif-
ferences in genomic alterations in biologic pathways between
ADC and SCC are beginning to be elucidated [1, 2]. Therapies
targeting HER2 (trastuzumab) and vascular endothelial
growth factor (ramucirumab) are applicable only to adenocar-
cinomas [3–5] of the esophagus and EGJ.
Esophageal cancer is ranked as the sixth leading cause of
cancer-related deaths. In 2012, 400,000 deaths were reported
globally due to esophageal cancer [6]. Although the incidence
of adenocarcinoma is increasing in Western countries, esoph-
ageal squamous cell carcinoma (ESCC) is the major histology
in Asian countries including Japan.
Smoking and alcohol intake, known to be the major risk
factors for this cancer, exert synergistic effects on carcinogen-
esis [7]. Long-term exposure to carcinogens related to
smoking and aldehyde, a metabolite of alcohol, produces
DNA damage and a range of genetic changes [8]. Although
driver gene mutations have not been detected in ESCC, the
somatic mutation rate in ESCC is relatively high compared
with other solid tumors [9, 10].
A multidisciplinary approach, including surgery and
radiotherapy, is important for ESCC. Chemotherapy is
standard for patients with distant metastases. Commonly
used agents include 5-fluorouracil, platinum agents, and
taxanes, though they are associated with limited clinical
benefit [11–14].
Although molecular targeting agents remarkably improve
the outcome of several types of solid tumors, no agents have
shown clear efficacy in ESCC up to now [15, 16]. However,
the pace of development of cancer immunotherapies is accel-
erating. Clinical evidence of the efficacy of immune check-
point inhibitors and adoptive immunotherapies, complete with
tumor-infiltrating lymphocytes and tumor-specific receptor
gene-modified T cells, herald the onset of a new era in cancer
immunotherapy.
This review summarizes the most recent status of immuno-
therapy for ESCC (Table 1).
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Checkpoint Inhibitors
Immune checkpoints are downregulators of the immune re-
sponse. Immune checkpoint blockade has drastically changed
the treatment of melanoma, and its effectiveness is being ex-
plored in other tumor types, including gastrointestinal malig-
nancies [17]. Programmed death-ligand 1 (PD-L1) expression
rates, associated with favorable overall survival (OS) in
ESCC, have been reported to range from 41.9 to 84.5%
[18–20]. Since PD-L1 expression is known to be induced by
activated T cells, agents targeting PD-L1 may be effective in
PD-L1+ ESCC patients [21].
An increase in the burden of nonsynonymous mutations in
tumors has been associated with improvements in objective re-
sponse and long-lasting clinical benefit as well as progression-
free survival (PFS). Efficacy has also been correlated with mo-
lecular smoking signature, a higher neoantigen burden, and mu-
tations in the DNA repair pathway. Each of these factors has also
been associated with mutation burden [22].
As mentioned above, the somatic mutation rate in ESCC is
relatively high compared with that of other solid tumors [9,
10]. Patients with esophageal cancer sometimes develop head
and neck cancer at the same time or after treatment, because
these cancers can arise by the same etiology and carcinogen-
esis. This possibility was suggested by the “field cancerization
theory,” first proposed in 1958, as due to exposure of multiple
portions of the upper digestive tract to the same carcinogen,
such as tobacco or alcohol [23].
Pembrolizumab, an anti-PD-1 antibody, received FDA ap-
proval for use in patients with recurrent or metastatic head and
neck squamous cell carcinoma and disease progression concur-
rent with or following platinum-containing chemotherapy. This
approval was based on data obtained from the KEYNOTE-012
study; this study included subjects with an ECOG performance
score of 0 or 1 who had recurrent or metastatic head and neck
squamous cell carcinoma and disease progression at the time of
or subsequent to platinum-containing chemotherapy or after
platinum-containing chemotherapy given as part of induction,
concurrent, or adjuvant therapy. According to the FDA approval
summary, the objective response rate for these 174 patients was
16%, with a response lasting ≥6 months in 23 of 28 responding
patients [24].
Doi et al. showed that pembrolizumabwas active in pretreated
esophageal cancer patients with PD-L1-expressing tumors (>1%
PD-L1-positive tumor cells and/or tumor stroma), with a partial
response (PR) rate of 30.4% (40.0% for adenocarcinoma, 29.4%
for squamous cell); there were no complete responses (CR). A
total of 52.2% of patients showed some degree of tumor shrink-
age andmanageable side effects [25••]. In this study, the six-gene
signature (IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, INF-γ)
captures part of a complex signaling pathway related to pre-
existing INF-γ adaptive immune response within the tumor mi-
croenvironment [26••]. Kojima et al. also reported data on
nivolumab, a human monoclonal IgG4 PD-1 immune check-
point inhibitor antibody, for patients with advanced ESCC not
preselected by PD-L1 status, with a PR rate of 15.6% and a CR
rate of 1.6%. The median overall survival (OS) was 12.1 months
in 64 evaluable patients. The incidence of drug-related serious
adverse events was 11 events (9/65 patients): lung infection (2
[3.1%]), dehydration (2 [3.1%]), interstitial lung disease (2
[3.1%]), diarrhea (1 [1.5%]), fatigue (1 [1.5%]), hepatic dysfunc-
tion (1 [1.5%]), hypernatremia (1 [1.5%]), and dyspnea (1
[1.5%]). The patients with grade 3 pneumonitis improved with
supportive care. There were no treatment-related deaths [27•].
The results of these studies show that anti-PD-1 antibody
therapy is a potential treatment in patients with ESCC. Other
studies of interest include a phase III trial of nivolumab
(Opdivo®, Squibb, Princeton NJ, USA), an anti-PD-1 antibody,
for patients with unresectable advanced or recurrent esophageal
cancers (JapicCTI-153026; NCT02569242). A phase III study of
pembrolizumab (Keytruda®, Merck, Kenilworth, NJ, USA) is
being conducted on patients with advanced ESCC or ADC in the
esophagus or esophagogastric junction progressing after the first-
line therapy (NCT02564263). Other anti-PD-1 antibodies are
being evaluated for adjuvant therapy.
Chemokines and chemokine receptors control the migra-
tion and homing of cells in the body. One promising target for
novel cancer immunotherapy is the CC chemokine receptor 4
(CCR4). Mogamulizumab (KW0761), the first biologic agent
targeting CCR4, obtained Japanese licensure for use in the
treatment of adult T cell leukemia/lymphoma (ATL) in 2012.
CCR4 is expressed on CD45RA–FOXP3 high CD4+ effector
regulatory T (Treg) cells. In a phase Ia study in patients with
CCR4-negative advanced or recurrent solid cancers,
mogamulizumab was tested for its ability to deplete effector
Treg cells and thereby strengthen the anti-cancer immune re-
sponse. The tolerability and safety of mogamulizumab by in-
fusion at a dose between 0.1 and 1.0 mg/kg were demonstrat-
ed, and dose-limiting toxicity was not observed. Four of the
ten patients (three of seven lung and one of three esophageal
cancer patients) showed stable disease throughout treatment
and were long-term survivors [28•, 29]. Now, a phase Ib study
in 40 patients with advanced or recurrent cancer who are
assigned at a 1:1 ratio to 0.1 or 1.0 mg/kg mogamulizumab
is ongoing (NCT01929486).
Checkpoint inhibition alone is not enough to promote
tumor regression in a majority of cancer patients. For a
robust therapeutic immune response, it is important not
only to block negative regulatory receptors but also to
enhance and trigger positive costimulatory signals.
Novel pharmacologic agents that target other immune
checkpoints and costimulatory receptors, including
CTLA4, OX40, 4-1BB, and LAG-3, are currently being
evaluated in a wide variety of tumors, including ESCC. In
addition, there are significant efforts underway to evaluate
combinations of immune checkpoint inhibitors with a
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variety of other anti-cancer therapies, including radiation,
surgery, and cytotoxic chemotherapy.
Combining Immune Checkpoint Inhibitors
with Radiation
Recently, increased knowledge of T cell regulatory mechanisms
has resulted in the development of a novel class of immune
checkpoint inhibitors with strong clinical efficacy against a wide
range of malignancies, including those which were not previous-
ly considered sensitive to immunotherapy. This has led to a
renewed focus on the possibility of synergy with older anti-
cancer therapies such as radiation therapy (RT).
The use of RT as definitive or palliative treatment for some
malignancies has been well established. Recently, however,
the possibility of using RT in combination with immunother-
apies has gained attention. In addition to control of tumor
growth, RT exerts a range of immunomodulatory effects on
the tumor and its microenvironment. These serve to prime the
tumor for an immune-mediated response [30].
Radiation is the foundation of treatment for ESCC.
Approaches to integrate immune checkpoint inhibition into
radiation-based therapy bring a range of challenges.
Radiation is known to produce immune-mediated abscopal
effects; proposed mechanisms include the recruitment of T
cells into the microenvironment, secretion of cytokines, and
enhancement of tumor antigen presentation [31, 32].
Interestingly, pre-clinical data indicate that increased PD-L1
expression in irradiated tumors suppresses the radiation-
induced anti-tumor properties of effector T cells [33]. This
has many therapeutic implications, particularly in locally ad-
vanced ESCC, in which the anti-tumor response might by
maximized by the combination of anti-PD-1 antibodies and
radiation. Radiation increases tumor antigen presentation and
potentiates the checkpoint inhibitor-induced anti-tumor re-
sponse [34]. A number of clinical trials to evaluate
pembrolizumab in combination with radiation are currently
underway. Two studies include the following:
& Pembrolizumab with brachytherapy for the initial treat-
ment of metastatic esophageal cancers (NCT02642809).
& Pembrolizumab and palliative radiation therapy for pa-
tients with metastatic esophageal, stomach, or EGJ cancer
(NCT02830594).
Peptide Vaccines
One area of oncology research attracting substantial and grow-
ing interest is active cancer immunotherapy. One attractive
option is peptide vaccines, which involve the use of isolated
immunogenic tumor-associated antigen (TAA) epitopes to
cause an anti-cancer immune response. Peptide vaccines are
easily administered and are minimally toxic. Multiple TAA-
derived peptides have been identified and evaluated with var-
ious vaccine strategies currently under clinical investigation.
Findings to date have suggested that the use of vaccines in
patients with minimal residual disease may be more effica-
cious than targeting patients with broadly disseminated meta-
static disease that tends to confer immunosuppression.
Clinical trials have indicated that achieving maximum ef-
ficacy may require that vaccines be tailored for particular can-
cer subtypes. Further, many of the large number of immuno-
modulators now in development have shown possible synergy
with peptide vaccines. One current focus of attention is tumor-
specific neoantigens, and clinical trials of individualized pep-
tide vaccinations that target individual neoantigens are now in
progress.
Progressively growing tumors contain mutant tumor
antigen-specific T cells. These are reactivated after treat-
ment with anti-PD-1 and/or anti-CTLA-4, and although
they show some overlap, their transcriptional profiles
are mostly treatment-specific, giving them the ability
to mediate tumor rejection. Tumor-specific mutant anti-
gens are thus not only major targets in checkpoint
blockade therapy but can be further used in the devel-
opment of personalized and cancer-specific vaccines as
well as in the investigation of the mechanisms underly-
ing the various checkpoint blockade treatments [35].
One peptide, the 20-mer NY-ESO-1f, contains many epi-
topes that are recognized with distinct specificity by CD4 and
CD8 T cells. Of the ten patients, two vaccinated patients with
lung cancer and one with esophageal cancer showed stable
disease. This study shows that the NY-ESO-1f peptide vaccine
was well tolerated and elicited humoral, CD4, and CD8 T cell
responses in immunized patients [36]. The immune response
induced by the vaccination could make the prognosis better
for advanced ESCC.
In a phase I dose-escalation trial of two dose levels of
CHP-NY-ESO-1 vaccine, complex vaccine (drug code:
IMF-001) consisting of recombinant NY-ESO-1 protein
and cholesteryl hydrophobized pullulan (CHP), in patients
with ESCC [37], the CHP-NY-ESO-1 vaccine was con-
firmed to be safe and to induce immunogenicity in pa-
tients with antigen-expressing ESCC. The higher dose in-
duced an antigen-specific immune response and better
survival benefits, even for patients with a poorer progno-
sis. From the results of these studies, a randomized mul-
ticenter phase II trial of adjuvant IMF-001 after curative
resection for esophageal cancer with NY-ESO-1 antigen is
now ongoing (UMIN000007905).
The safety of combination treatment using a multipeptide
vaccine with CRT has been confirmed, and its use may be
effective in patients with unresectable ESCC [38].
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However, peptide vaccine therapy targeting common self-
antigens has not yet been approved in Japan. Some of these
vaccines have been investigated in ESCC patients.
Ongoing trials are as follows:
A multicenter, randomized, double-blind, placebo-con-
trolled, phase III study of S-588410, a cancer peptide
vaccine containing five human leukocyte antigen
(HLA)-A*2402-restricted epitope peptides, as adjuvant
therapy after curative resection in patients with esopha-
geal cancer (UMIN000016954).
A randomized multicenter trial of adjuvant IMF-001 with
NY-ESO-1 antigen (phase II study) after curative resec-
tion for esophageal cancer (UMIN000007905).
Phase 1 study of HSP105-derived peptide vaccine for
patients with advanced esophageal cancer/colorectal can-
cer (UMIN000017809).
Adoptive T Cell Therapy
Another promising treatment is adoptive immunotherapy.
This involves the administration of T cells which have been
manipulated to target a tumor. These therapies have shown
marked efficacy in the treatment of hematologic malignancies
as well as certain solid tumors, including melanoma.
Genetic tools which efficiently engineer T cell specificity
and enhance T cell function have been developed. Chimeric
antigen receptors (CAR) use antibody-variable segments to
target specificity at cell surface molecules. T cell receptors
(TCR) are used to redirect T cells to intracellular target pro-
teins; these are present within the peptide-binding groove of
HLA molecules in fragment form.
A clinical trial of CAR-modified T cells redirected to target
the B cell lineage antigen CD19 produced marked clinical re-
sults in patients with chronic lymphocytic leukemia [39].
Similar impressive responses were obtained in patients with
melanoma and synovial cell carcinoma using TCR-modified T
cells redirected to targetMART-1, a melanocyte lineage antigen,
and NY-ESO-1, a testis-cancer antigen [40]. Nevertheless, most
of these clinical responses were associated with both on- and
off-target toxicity, and death from complications has occurred in
some patients receiving gene-modified T cells.
In a phase I trial which evaluated the use of TCR gene-
transduced T cell transfer in recurrent MAGE-A4-expressing
ESCC, TCR-transduced cells were identified in the peripheral
blood for 1 month in dose-proportional levels. In five patients,
these persisted for more than 5 months. Despite this long
persistence of the transferred T cells, seven patients showed
tumor progression within 2 months after treatment, whereas
three patients with minimal baseline tumor lesions survived
longer than 27 months [41•].
Because they allow for more precise T cell targeting, the
emerging technology of chimeric antigen receptor T cells
(CAR-T) has transformed the field of adoptive T cell therapy.
A number of trials are now investigating adoptive T cell trans-
fer techniques in patients with ESCC. These include the
following:
A phase I study of T cells engineered to recognize the
MAGE-A4 marker (TBI-1201) in patients with solid tu-
mors, including ESCC (NCT02096614).
A phase I study of T cells engineered to recognize the
NY-ESO-1 marker (TBI-1301) in patients with solid tu-
mors, including ESCC (NCT02366546).
T cell receptor-transduced T cell targeting NY-ESO-1 for
treatment of patients with NY-ESO-1-expressing malig-
nancies (NCT02457650).
Oncolytic Viruses as Immunotherapy
The use of oncolytic viruses for previously untreatable cancers
has recently been proposed [42]. These viruses selectively
replicate in tumor cells, causing them to lyse, and their use
as novel anti-cancer agents has been closely investigated.
These vectors are assumed to undergo selective viral propa-
gation within the tumor cell and cause virus-mediated lysis of
tumor cells, while having no effect on normal tissues.
Talimogene laherparepvec (T-VEC), the first oncolytic vi-
rus to show positive results in a phase III clinical trial, is
derived from the herpes simplex virus [43]. It received FDA
approval for advanced metastatic melanoma in October 2015.
Engineered oncolytic viruses induce tumor cell lysis and
inflammation. They increase T cell numbers and activity and
thereby strengthen the anti-tumor response after treatment
with anti-CTLA-4 or anti-PD-1 agents [44]. These combina-
tions might enhance efficacy by negating the ability of the
local tumor microenvironment to suppress the induced im-
mune response [45]. Some reports have indicated that combi-
nation of talimogene laherparepvec with a checkpoint inhibi-
tor might show promising anti-tumor activity [46, 47]. Future
research should be directed at how better to suppress anti-viral
immune responses and minimize pathology while simulta-
neously enhancing anti-tumor immunity.
A recent study described a phase I/II trial of a novel
telomerase-specific oncolytic virus, OBP-301, given by endo-
scopic intratumoral administration together with radiation in
elderly patients with ESCC. This study enrolled six patients in
a single cohort. Objective responses were CR in two patients
and partial response (PR) with tumor regression in one [48•].
The results showed the feasibility and tolerability of multiple
courses of endoscopic OBP-301 injection together with
locoregional radiotherapy in patients with ESCC as well as
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apparent clinical benefit. Endoscopic treatment for ESCC,
such as endoscopic mucosal resection, is actively performed
worldwide; endoscopic intratumoral injection of oncolytic vi-
rus is not a difficult technique. These findings indicate the
potential of oncolytic virotherapy in the treatment of ESCC.
A clinical study of a tumor-selective oncolytic adenovirus
(Telomelysin) in combination with ionizing radiation for head
and neck and thoracic malignant tumors, including esophageal
cancer (UMIN000010158), is ongoing.
Combination Cancer Immunotherapy
Immune responses against tumors involve positive and nega-
tive feedback loops of numerous host immune cells and mole-
cules around the tumor. Combination cancer immunotherapy,
using therapies with different modes of action has attracted
much interest and is now considered a mainstream develop-
mental approach. Combination therapies include conventional
chemotherapy as well as biological agents and radiotherapy.
Any future success is likely contingent on the ability to maxi-
mize the gathering of specific information on the interaction of
immunotherapies with concomitant medications with regard to
their mechanisms of action, doses, and dosing regimens.
CTLA-4 and PD-1 regulate different inhibitory pathways,
and combination therapies with antibodies targeting both mol-
ecules have been shown to improve anti-tumor response in a
mouse model. In a phase I clinical trial of anti-CTLA-4 block-
ade in combination with anti-PD-1 inhibition, the combination
of ipilimumab and nivolumab provided high tumor regression
rates in patients with melanoma [49]. In fact, the results of the
randomized phase III study evaluating this combination in mel-
anoma patients have been recently communicated, which in
2015 led to FDA approval. These promising results have led
to a number of phase I trials currently testing combination treat-
ment with an anti-CTLA-4 and an anti-PD-1/PD-L1 antibody.
Ongoing trials are as follows:
Study of combination therapy with mogamulizumab
(KW-0761) and nivolumab (ONO-4538/BMS-936558)
in subjects with advanced solid tumors, including esoph-
ageal cancer (NCT02476123).
Phase I study of pre-operative combination therapy with
mogamulizumab (anti-CCR4) and nivolumab (anti-PD-
1) against solid cancer patients (UMIN000021480).
Conclusion
Immunotherapy for the treatment of patients with advanced
ESCC has shown significant recent advances.
In particular, the value of immune checkpoint inhibitors
has been comprehensively demonstrated in the treatment of
melanoma and nonsmall cell lung cancer, and emerging effi-
cacy data in advanced ESCC. Among new approaches, thera-
peutic peptide vaccines, oncolytic Viruses, and adoptive Tcell
therapy have shown potential in treatment of ESCC. These are
under active development. The complex biology and variety
of tumor evasion strategies means that combination strategies
are very important for future development.
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